Geode Capital Management LLC Sells 8,277 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Geode Capital Management LLC trimmed its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 0.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,874,922 shares of the biotechnology company’s stock after selling 8,277 shares during the quarter. Geode Capital Management LLC’s holdings in Anavex Life Sciences were worth $20,142,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 1,191 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Anavex Life Sciences by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 1,671 shares during the period. Foster Victor Wealth Advisors LLC lifted its holdings in shares of Anavex Life Sciences by 5.6% in the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 2,000 shares in the last quarter. Opus Capital Group LLC boosted its position in shares of Anavex Life Sciences by 6.1% during the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock worth $373,000 after buying an additional 2,000 shares during the period. Finally, Nwam LLC raised its position in Anavex Life Sciences by 0.3% in the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock valued at $9,806,000 after buying an additional 2,575 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL opened at $8.95 on Friday. The stock has a 50 day moving average price of $8.72 and a 200 day moving average price of $8.64. The stock has a market capitalization of $761.32 million, a PE ratio of -16.27 and a beta of 0.80. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, research analysts forecast that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.